Catalyst overview
Research summary
This catalyst tracks a Phase 2 data readout for TP-04 in Ocular Rosacea. The expected timing is based on the latest available company guidance and may change.
8/6/25- Initiate study in the H2 2025. 11/04/25:- Phase 2 ocular rosacea study initiation planned for December 2025 with topline data expected by year-end 2026. 02/23/26:- Phase 2 ocular rosacea trial initiated; topline data now expected in H1 2027. 05/06/26:- Phase 2 ocular rosacea trial progressing; topline data remains expected in H1 2027. 08/06/26:- KORE Ph2 topline data remains expected in H1 2027.
Verification
Confirm timing and program details against the company announcement or filing.